Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of tripterine to preparation of medicine treating degenerative retinopathy related diseases

A technology of tripterine and retinal degeneration, applied to metabolic diseases, sensory diseases, drug combinations, etc., to achieve remarkable results

Inactive Publication Date: 2016-02-24
YUEYANG INTEGRATED TRADITIONAL CHINESE & WESTERN MEDICINE HOSPITAL SHANGHAI UNIV OF CHINESE TRADITIONAL MEDICINE +1
View PDF3 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0011] So far, there are no reports in the literature that tripterine has been used in the treatment of diseases with photoreceptor cell death as the core pathology and oxidative stress of retinal pigment epithelial cells or retinal photoreceptor cells (including age-related macular degeneration, retinitis pigmentosa, Stargardt et al. pharmacological activity in retinal degenerative diseases such as retinal degeneration, cone-rod dystrophy, and diabetic retinopathy)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of tripterine to preparation of medicine treating degenerative retinopathy related diseases
  • Application of tripterine to preparation of medicine treating degenerative retinopathy related diseases
  • Application of tripterine to preparation of medicine treating degenerative retinopathy related diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] In this embodiment, we have clarified the intervention effect of tripterine on the retinal photodamage mouse model through non-invasive retinal fundus optical coherence tomography OCT technology and immunohistochemical staining. The research results show that tripterine can effectively interfere with the death of photoreceptor cells and the occurrence of retinal degeneration, and have a significant protective effect on the structure of the retina.

[0048] 1. Method

[0049] 1. Drug: tripterine, purchased from Sigma (C0869, Lot#113M4601V and Lot#042M4608V), with a purity of ≥98%.

[0050] 2. Animal model: 4-6 weeks old female Balb / c mice (Slack, Shanghai) were used for experiments. Mice were randomly divided into normal control group, photodamage model control group and Celastrol treatment group, with 8 mice in each group. The normal control group did not receive white light stimulation, but only received solvent DMSO treatment, and the other groups received 50 μl sol...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of tripterine to preparation of medicine treating degenerative retinopathy related diseases. A mouse model suffering from retinal photodamage is adopted to simulate a common pathological link in various degenerative retinopathy generation processes, that is, death of photoreceptor cells; the photoreceptor cell death preventing function and the degenerative retinopathy preventing function of tripterine are researched, wherein the results show that tripterine can be used for inhibiting mass dead of the photoreceptor cells and structural damage and functional injury of a retina caused by photodamage, and is very obvious in degenerative retinopathy treating effect. Therefore, tripterine can be used for preparing medicine treating various types of degenerative retinopathy including age related macular degeneration, retinitis pigmentosa, Stargardt disease, cone-rod dystrophy, diabetic retinopathy and the like, or preparation of reagents used in related scientific researches.

Description

technical field [0001] The present invention relates to the new medical application of the compound, specifically, relates to the preparation and prevention of Celastrol in the preparation and prevention of retinal photoreceptor cell death as the core pathology including age-related macular degeneration, Stargardt disease, cone-rod cell The application of drugs for retinal degenerative diseases including malnutrition, retinitis pigmentosa and diabetic retinopathy. Background technique [0002] Retinal degenerative diseases with retinal photoreceptor cell death as the core pathology include age-related macular degeneration, Stargardt disease, cone-rod cell dystrophy, retinitis pigmentosa and diabetic retinopathy, etc., which can cause severe visual impairment Even blindness. [0003] Age-related macular degeneration is one of the most common major types of retinal degenerative diseases that seriously endanger vision health and even cause blindness worldwide. Epidemiological...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/56A61P27/02A61P3/10
CPCA61K31/56
Inventor 陈瑜朱维良张腾卞敏娟张勇崔金刚杜宵烨王培伟于心同陈照强李波徐子健
Owner YUEYANG INTEGRATED TRADITIONAL CHINESE & WESTERN MEDICINE HOSPITAL SHANGHAI UNIV OF CHINESE TRADITIONAL MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products